WHO Foundation and Lilly launch $1.68 million obesity care collaboration through 2029
Lilly will give the WHO Foundation $1.68 million through 2029 to build obesity care capacity in lower-income countries, with no medicines, prices or US coverage terms disclosed.
The WHO Foundation announced on March 6, 2026 that it is collaborating with Eli Lilly and Company on an effort to strengthen health systems for obesity prevention and care, with Lilly committing $1.68 million to the Foundation through 2029 [1].
The WHO Foundation is an independent organization based in Geneva, Switzerland, created in 2020 to support the mission of the World Health Organization [1]. It says it mobilizes philanthropic capital and builds partnerships to advance health equity [1]. Lilly's funding is directed at what the announcement calls resource-limited settings, "where the need is greatest" [1].
The stated goals are broad. The Foundation says the work is meant to help countries assess care gaps, integrate evidence-based policies, develop training standards for the health workforce, and deliver "equitable, stigma-free care over time for all age groups," and to support early diagnosis and counseling [1].
"Addressing obesity at scale requires more than individual programs. It requires health systems that are prepared to respond across the life course," said Anil Soni, chief executive officer of the WHO Foundation [1].
Patrik Jonsson, executive vice president and president of Lilly International, said people living with obesity "deserve to receive the care they need to overcome this disease and avoid related health complications," and that the collaboration is intended to help countries assess care gaps and build prevention and care pathways [1].
The announcement lays out the scale of the problem using World Health Organization figures. In 2022, more than 2.5 billion adults and over 390 million children and adolescents worldwide were overweight, and 1 in 8 people were living with obesity [1]. Adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled [1]. Of the 2.5 billion adults who were overweight in 2022, 890 million were living with obesity; 43% of adults were overweight and 16% were living with obesity [1]. In 2024, 35 million children under age 5 were overweight, and in 2022, 160 million children and adolescents aged 5 to 19 were living with obesity [1].
The release also cites World Obesity Federation projections that the economic impact of overweight and obesity will surpass $4 trillion by 2035 [1].
Several things are not in the announcement. No specific obesity medicine is named, and there is no reference to GLP-1 drugs such as semaglutide, tirzepatide or orforglipron [1]. There is no commitment to supply medicines, no pricing terms, no list of countries, and no description of how the work will be measured [1]. A separate WHO Foundation release listed alongside this one describes an expanded collaboration with Novo Nordisk covering heart, kidney and metabolic diseases [1].
Why it matters for patients
The money is aimed at health systems outside the United States, so it does not change US drug prices, insurance coverage or pharmacy availability [1]. Nothing in the announcement commits Lilly to lower prices or expanded supply for any GLP-1 medicine, and no such terms were disclosed [1].
The two companies that dominate the obesity drug market, Lilly and Novo Nordisk, are now both funding work with the same foundation, which is an independent body that supports WHO's mission rather than WHO itself [1]. The announcement does not say how much influence the companies have over which countries or programs are chosen [1].
For US patients, the practical relevance is mostly context: global health bodies are framing obesity as a systems problem that requires training, diagnosis and long-term care, not only prescriptions [1]. How that framing translates into treatment access in low-income countries has not been reported [1].
What happens next
The funding is committed through 2029 [1]. No country list, program milestones, reporting schedule or criteria for measuring results have been disclosed [1]. Whether the collaboration will expand beyond the initial $1.68 million, and whether it will eventually include medicine access or pricing arrangements, has not been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.